Optimizing Treatment Strategies in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualized Therapy for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 155,870 deaths from lung cancer in 2018, accounting for around 29% of all cancer deaths. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around EGFR mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer.

Molecular testing has now become a critical part of selecting treatment for patients with advanced NSCLC. Nearly two-thirds of NSCLC patients who are EGFR mutation-positive and experience disease progression after being treated with an EGFR-TKI develop a T790M resistance mutation, for which there have been limited treatment options. However, new indications and agents are now becoming available for patients with EGFR-TKI that has a T790M resistance mutation. Additionally, the first-line management of advanced EGFR-mutated advanced NSCLC has begun to change with new indications bringing more options to the table. As non-small cell lung cancer therapies and treatments continue to both grow and change, it is imperative that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options that can greatly improve a patient’s quality of life and prognosis.

Upon completion of this activity, participants will be able to:

  • Explore the efficacy, safety and tolerability of current and emerging targeted and immunotherapeutic treatment options in the management of advanced non-small cell lung cancer (NSCLC)

  • Examine the recent advances around targeted treatment options for advanced EGFR-mutated NSCLC in the first-line setting based on tumor and patient specific factors

  • Assess treatment options and management strategies for patients with advanced EGFR-Mutated NSCLC who develop a T790M resistance mutation

  • Explore the role of immunotherapy in the first-line treatment of advanced non-squamous and squamous NSCLC based on new clinical data

  • Compare the relative strengths and limitations of liquid biopsy against those of conventional tissue biopsy

  • Discuss managed care considerations of current and emerging immunotherapeutic and targeted treatment options by exploring where these agents fit into the current advanced NSCLC management paradigm
     

Faculty: H. Jack West, MD
Medical Oncology
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute

Disclosure:

Dr. West serves on an advisory board for AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Merck, and Pfizer. He serves as a consultant for AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Merck, and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue